13 February 2025
 |
ECO Animal Health Group plc
("ECO" or the "Company")
Notice of R&D Day
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it will be holding an in-person and virtual R&D Day for investors and analysts on 13 March 2025, from 14:00 GMT at Andaz London, 40 Liverpool St, London EC2M 7QN.
The event will be led by David Hallas, CEO, and Chris Wilks, CFO, alongside senior leaders from across the Company and an industry expert. Attendees will have the opportunity to gain valuable insights on how the next generation of assets in ECO's R&D pipeline are driving long-term value creation and future proofing the business through innovations in preventative animal health.
To confirm your interest in the R&D Day please contact ecoanimalhealth@consilium-comms.com.
-Ends-
For further information please contact:
| |
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.